瑞博生物-B(06938.HK)：RBD5044注射液获国家药监局的II期临床试验默示许可

Core Viewpoint - Reborn Bio-B (06938.HK) has received implied approval from the National Medical Products Administration of China for the Phase II clinical trial of its self-developed RBD5044 injection, a targeted siRNA drug aimed at APOC3 [1] Group 1: Product Development - RBD5044 is designed to target APOC3, a protein primarily synthesized in the liver that plays a crucial role in lipid metabolism [1] - The drug addresses complications associated with hypertriglyceridemia, providing a treatment option for managing dyslipidemia [1]